Equities

IXICO PLC

IXICO PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.10
  • Today's Change-0.55 / -6.36%
  • Shares traded46.88k
  • 1 Year change-62.33%
  • Beta0.7357
Data delayed at least 20 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.

  • Revenue in GBP (TTM)6.67m
  • Net income in GBP-1.18m
  • Incorporated1995
  • Employees89.00
  • Location
    IXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
  • Phone+44 203 763 7499
  • Fax+44 207 209 2473
  • Websitehttps://ixico.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Voyager Life PLC314.00k-1.10m1.35m28.00--2.12--4.29-0.0912-0.09120.02530.0440.18971.583.8511,214.29-66.51---77.02--41.72---350.64--2.83-69.500.4625--59.55---38.70------
Nuformix PLC0.00-436.95k1.56m2.00--0.3371-----0.0006-0.00060.000.00560.00-------9.50---9.95--------------0.00--------------
N4 Pharma PLC0.00-925.31k1.81m5.00--1.09-----0.0042-0.00420.000.00620.00----0.00-59.56-58.71-65.34-63.61-------8,155.51---1,910.050.00------33.35------
ReNeuron Group Plc249.00k-5.07m1.93m34.00--0.7966--7.75-0.0888-0.08880.00440.04240.0246--0.64427,323.53-50.10-43.12-101.09-58.50-----2,037.35-714.73----0.1247--31.5165.2644.18---1.31--
Evgen Pharma PLC838.00k-3.35m2.41m7.00--0.6113--2.87-0.0122-0.01220.00310.01430.1406--1.81119,714.30-56.25-42.37-60.57-46.32-----400.12-2,324.84----0.00-------48.10---32.24--
Hellenic Dynamics PLC-100.00bn-100.00bn3.40m25.00--4.48----------0.006----------------------------0.3029--------------
Fusion Antibodies PLC1.58m-2.84m3.67m50.00--1.57--2.33-0.0861-0.08610.04360.02450.52293.151.8831,580.00-93.94-31.29-130.56-37.72-7.4142.58-179.67-48.252.32--0.0313---39.551.52-116.33---23.83--
IXICO PLC6.67m-1.18m4.18m89.00--0.3659--0.6275-0.0244-0.02440.1380.23640.4822--2.8274,887.64-8.524.35-9.575.3349.0662.09-17.676.61----0.03270.00-22.894.32-214.15--92.12--
Genflow Biosciences PLC0.00-1.18m4.24m0.00--2.47-----0.004-0.0040.000.00590.00-------48.01---51.61-------------6,299.750.00-------35.13------
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m4.68m7.00--2.12-----0.0044-0.00440.000.0020.00----0.00-82.98-56.41-104.70-66.13------------0.00-------26.16------
ValiRx Plc0.00-2.41m5.10m8.00--0.937-----0.0256-0.02560.000.04110.00----0.00-69.67-58.85-69.21-68.96-----------575.810.0072-------55.87------
BSF Enterprise PLC12.94k-1.50m5.94m4.00--1.22--459.19-0.0159-0.01590.00010.0470.00282.110.08373,235.00-32.30---34.46---451.16---11,600.08--8.16-154.860.0313-------61.40------
Data as of Mar 28 2024. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX

Institutional shareholders

50.85%Per cent of shares held by top holders
HolderShares% Held
BGF Investment Management Ltd.as of 04 Dec 20238.92m18.46%
Octopus Investments Ltd.as of 04 Dec 20236.41m13.25%
Canaccord Genuity Wealth Ltd.as of 30 Mar 20214.68m9.69%
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 20241.76m3.63%
City Asset Management Plcas of 29 Jan 20241.43m2.95%
ICBC Standard Bank Plcas of 01 Feb 2024610.00k1.26%
Pilling & Co. Stockbrokers Ltd.as of 01 Feb 2024267.00k0.55%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024223.00k0.46%
Acadian Asset Management LLCas of 01 Feb 2024151.00k0.31%
BG Fund Management Luxembourg SAas of 01 Feb 2024137.00k0.28%
More ▼
Data from 31 Dec 2023 - 17 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.